Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Pimavanserin in MDD with Inadequate Response
NCT03968159Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of pimavanserin in major depressive disorder (MDD), sponsored by Acadia Pharmaceuticals. Started Apr 2019; status: completed.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03968159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968159.